ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Highly-sensitized"

  • 2016 American Transplant Congress

    Donor HLA Specific IgM Antibody Measured on Day 14 Post-Transplantation Predicts Poor Graft Survival in HLA-Incompatible Renal Transplantation.

    A. Babu, A. Androeu, S. Daga, R. Higgins, D. Mitchell, D. Briggs, N. Khovanova, N. Krishnan.

    Renal Medicine, University Hospital Coventry and Warwickshire, Coventry, West Midlands, United Kingdom; Life Sciences, University of Warwick, Coventry, West Midlands, United Kingdom; Histocompatibility and Immunogenetics, NHS Blood and Transplant, Birmingham, West Midlands, United Kingdom; School of Engineering, University of Warwick, Coventry, United Kingdom.

    Introduction: Role of IgG antibodies against donor human leucocyte antigens (HLA) is established in renal transplant monitoring. Role of IgM donor HLA specific antibodies (DSA)…
  • 2016 American Transplant Congress

    EBV Sero-Positivity Does Not Reduce the Risk for EBV Viremia and/or Post-Transplant Lymphoproliferative Disorder (PTLD) in Patients (Pts) Receiving Belatacept (CTLA4Ig).

    J. Choi, B. Shin, J. Kahwaji, S. Ge, D. Thomas, A. Vo, O. Galera, R. Villicana, A. Peng, S. Jordan, M. Toyoda.

    Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.

    Introduction: CTLA4Ig is a novel immunosuppressive (IS) which acts through costimulatory blockade of T-cells and obviates the need for calcineurin inhibitor-based IS (CNI-IS). Despite benefits…
  • 2016 American Transplant Congress

    The Bacterial Enzyme IdeS, Inhibits HLA Antibody-Mediated NK Cell Activation and Cell Cytotoxicity (ADCC) In Vitro.

    S. Ge, M. Chu, J. Choi, S. Jordan, M. Toyoda.

    Transplant Immunology Laboratory, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles.

    Background: Antibody-mediated rejection (ABMR) is a major obstacle for successful transplantation in HLA-sensitized patients. ADCC is one of the primary mechanisms for ABMR. IdeS cleaves…
  • 2016 American Transplant Congress

    Virtual Crossmatching Under the New KAS: Safely Bypassing a Physical Crossmatch When Allocating Kidneys to Highly Sensitized Candidates.

    R. Bray,1 R. Parsons,2 N. Turgeon,2 H. Gebel.1

    1Pathology, Emory University, Atlanta, GA; 2Emory Transplant Center, Emory University, Atlanta, GA.

    AIM: On 12/4/2014, the OPTN implemented a new KAS for deceased donor(DD) transplants which, among many changes, increased priority for highly sensitized (HS) candidates (cPRA>98%).…
  • 2016 American Transplant Congress

    Impact of Angiotensin II Type I Receptor Antibody Positivity in Highly-HLA Sensitized (HS) Patients Transplanted After Desensitization (DES).

    A. Vo,1 C. Boutsicaris,1 X. Zhang,2 N. Reinsmoen,2 J. Choi,1 S. Jordan.1

    1Kidney Transplant, Cedars-Sinai Medical Center, LA, CA; 2HLA Laboratory, Cedars-Sinai Medical Center, LA, CA.

    Introduction: Angiotensin II type I receptor antibody (AT1R Ab) is a target for non-HLA antibodies. AT1R ab exert direct effects on endothelial and vascular smooth…
  • 2016 American Transplant Congress

    Role of Preformed IgM Donor Human Leucocyte Antigen (HLA) Specific Antibodies in HLA Incompatible Renal Transplantation.

    A. Andreou, A. Babu, T. Barber, R. Higgins, D. Briggs, D. Mitchell, N. Khovanova, T. Shaikhina, S. Daga.

    Renal, University Hospitals Coventry and Wawickshire, Coventry, United Kingdom; Life Sciences, University of Warwick, Coventry, United Kingdom; School of Mathematics and Engineering, University of Warwick, Coventry, United Kingdom.

    Introduction: Pre-transplant IgG antibody screening is common due to its established role of predicting rejection and graft survival; the role of pre-formed IgM human leukocyte…
  • 2016 American Transplant Congress

    First Experience with Obinutuzumab (Type II Anti-CD20) in Patients with Treatment-Resistant Glomerular Diseases and Antibody-Mediated Rejection.

    J. Choi, S. Jordan, A. Vo.

    Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.

    Introduction: There is extensive experience with rituximab (RTX,Type I anti-CD20) for desensitization (DES) and treatment of ABMR. There is also a comparable experience in treatment…
  • 2016 American Transplant Congress

    Alemtuzumab Is Safe and Effective Induction Therapy in Highly Sensitized (HS) Pediatric Patients Undergoing Transplantation.

    I. Kim,1 J. Choi,1 A. Vo,1 A. Kang,1 M. Toyoda,1 J. Mirocha,2 E. Kamil,1 S. Louie,1 O. Galera,1 S. Jordan,1 D. Puliyanda.1

    1Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; 2Biostatistics Core, Cedars-Sinai Medical Center, Los Angeles, CA.

    Introduction: Studies show that alemtuzumab, a potent lymphocyte-depleting agent, is well-tolerated in pediatric renal transplantation. We report on the use of alemtuzumab induction in HS…
  • 2016 American Transplant Congress

    Initial Experience with the Bacterial Enzyme IdeS® (IgG Endopeptidase) for Desensitization of Highly-HLA Sensitized (HS) Patients.

    S. Jordan,1 J. Choi,1 X. Zhang,1 M. Haas,2 A. Peng,1 J. Kahwaji,1 R. Villicana,1 A. Vo.1

    1Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; 2Pathology, Cedars-Sinai Medical Center, Los Angeles, CA.

    Introduction: The IgG degrading enzyme derived from Streptococcus pyogenes (IdeS®) is a 35k-Da cysteine protease that cleaves human IgG molecules at the lower hinge region…
  • 2016 American Transplant Congress

    Long-Term Assessment of the Safety and Efficacy of IVIG and Rituximab-Based Desensitization (DES).

    J. Choi, J. Kahwaji, A. Vo, S. Louie, A. Kang, A. Peng, R. Villicana, D. Puliyanda, I. Kim, S. Jordan.

    Comprehensive Transplantation Center, Cedars-Sinai Medical Center, Los Angeles, CA.

    Introduction: HLA sensitized patients constitute a growing number of ESRD patients with an immunologic barrier to successful transplantation. Desensitization (DES) therapies have emerged to address…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 15
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences